Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Status:
Terminated
Trial end date:
2015-09-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare progression-free survival (PFS) (based upon
investigator assessment using RECIST v1.1) in participants with platinum-resistant ovarian
cancer who receive combination therapy with EC145 and pegylated liposomal doxorubicin
(EC145+PLD) with that in participants who receive PLD and placebo.